Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $660.00 Price Target at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by research analysts at UBS Group from $595.00 to $660.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential upside of 1.91% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group raised their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Finally, Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $796.57.

Regeneron Pharmaceuticals Stock Up 0.1%

Shares of REGN stock traded up $0.76 during mid-day trading on Friday, hitting $647.63. The stock had a trading volume of 290,798 shares, compared to its average volume of 1,093,477. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $834.42. The firm’s 50-day moving average is $586.50 and its two-hundred day moving average is $567.49. The firm has a market capitalization of $68.64 billion, a P/E ratio of 15.50, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.46 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. World Investment Advisors bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $230,000. Envestnet Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 28.1% in the first quarter. Envestnet Asset Management Inc. now owns 116,727 shares of the biopharmaceutical company’s stock worth $74,031,000 after purchasing an additional 25,589 shares during the period. Alps Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 71.0% in the first quarter. Alps Advisors Inc. now owns 530 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 220 shares during the period. Finally, SteelPeak Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 28.1% during the 1st quarter. SteelPeak Wealth LLC now owns 3,615 shares of the biopharmaceutical company’s stock valued at $2,293,000 after purchasing an additional 792 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.